|Articles|June 3, 2010

Pharmaceutical Executive

  • Pharmaceutical Executive-06-03-2010
  • Volume 0
  • Issue 0

Jamie Peck, Rosetta

Independence equals creativity, and solutions

Global holding companies are, in reality, nothing more than loose confederations of independent agencies, each with their own profit and loss statements (P&Ls) and profit goals. This can create multiple layers of unnecessary bureaucracy and overhead, actually resulting in increased cost to the client.

Jamie Peck

In a word, independence gives birth to creativity. Rosetta's point of view is that independent alliances, while sometimes hard to centrally manage, are the most effective way to serve our global clients creatively. For Allergan EMEA, Rosetta has acted as a sole provider of all digital solutions in 11 countries. This has resulted in several award-winning digital solutions, all managed centrally from the US.

By recognizing the inverse dynamic of emerging media in emerging regions, HC marketers can leverage the power of an entire arsenal of tools. Outside of the US, the Web is merely a portal or gateway for the patient and provider to access a myriad of other digitally enabled media outlets. By accessing these other channels (mobile, social, gaming, etc.), we are able to meet all of the targets' needs—emotional, educational, and value based—through the devices they rely on every day.

Articles in this issue

over 16 years ago

Scott D. Cotherman, CAHG

over 16 years ago

Phil Deschamps, GSW Worldwide

over 16 years ago

Jay Carter, AbelsonTaylor

over 16 years ago

Michael McLinden, MCK

over 16 years ago

Jeff Burke, MicroMass Communications

over 16 years ago

Jon Hussey, Palio

over 16 years ago

Maureen C. Regan, RCW Group

Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.